drugset
drugset / Trial / NCT06493240

Neoadjuvant Long-course Chemoradiotherapy Followed by Immunotherapy for Locally Advanced Mid-low Rectal Cancer

NCT06493240 ↗

Phase 2 Completed 30 enrolled Peking University People's Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the effect of capecitabine-based long-term radiotherapy followed by 3 cycles Sintilimab (PD-1 inhibitor) in patients with locally advanced rectal cancer.

Timeline

Start
2023-01-01
Primary completion
2025-04-01
Completion
2025-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sintilimab Monoclonal antibody 200 mg —

Indications

No indication recorded.